Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis

Toyoda, M. ; Nakamura, M. ; Makino, T. ; Hino, T. ; Kagoura, M. ; Morohashi, M.

Oxford, UK : Blackwell Science Ltd
Published 2002
ISSN:
1365-2133
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Summary Background Neurogenic components, such as neurotrophic factors and neuropeptides, are probably involved in the pathogenesis of atopic dermatitis (AD) via the neuroimmunocutaneous system. Numerous in vitro and in vivo studies have shown that nerve growth factor (NGF), the best-characterized member of the neurotrophin family, modulates the synthesis of the neuropeptide substance P (SP), both of which may be associated with the pathogenesis of human allergic diseases. Objectives To evaluate the levels of NGF and SP in the plasma of patients with AD and to examine their possible correlation with disease activity. Methods We measured plasma levels of NGF by an immunoenzymatic assay and of SP by aradioimmunoassay in 52 patients with AD, and compared them with 35 normal non-atopic controls. The severity of the disease in AD patients was evaluated using validated clinical scoring systems. Results Patients with AD had significant increases in plasma levels of NGF and SP compared with controls (P 〈 0·0005 and P 〈 0·0001, respectively). A positive correlation between the plasma levels of NGF and SP was found in AD patients (correlation coefficient, Cc = 0·920, P 〈 0·0001). There was a significant correlation of plasma NGF and SP levels with disease activity evaluated using three different scoring systems: the grading system of Rajka and Langeland (P 〈 0·001 and P 〈 0·01, respectively), the objective Severity Scoring of AD (Cc = 0·656, P 〈 0·005 and Cc = 0·752, P 〈 0·0005, respectively) and the Eczema Area and Severity Index (Cc = 0·740, P 〈 0·001 and Cc = 0·765, P 〈 0·005, respectively). Conclusions These data represent the first reported evidence of increased plasma levels of NGF and SP in an allergic human skin disease. They suggest that these neurogenic factors systemically modulate the allergic response in AD, probably through interactions with cells of the immune-inflammatory component. In addition, NGF and SP may be useful markers of disease activity in patients with AD.
Type of Medium:
Electronic Resource
URL:
_version_ 1798290094787919872
autor Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
autorsonst Hino, T.
Kagoura, M.
Morohashi, M.
book_url http://dx.doi.org/10.1046/j.1365-2133.2002.04803.x
datenlieferant nat_lic_papers
hauptsatz hsatz_simple
identnr NLZ242123910
insertion_date 2012-04-27
issn 1365-2133
journal_name British journal of dermatology
materialart 1
notes Summary Background Neurogenic components, such as neurotrophic factors and neuropeptides, are probably involved in the pathogenesis of atopic dermatitis (AD) via the neuroimmunocutaneous system. Numerous in vitro and in vivo studies have shown that nerve growth factor (NGF), the best-characterized member of the neurotrophin family, modulates the synthesis of the neuropeptide substance P (SP), both of which may be associated with the pathogenesis of human allergic diseases. Objectives To evaluate the levels of NGF and SP in the plasma of patients with AD and to examine their possible correlation with disease activity. Methods We measured plasma levels of NGF by an immunoenzymatic assay and of SP by aradioimmunoassay in 52 patients with AD, and compared them with 35 normal non-atopic controls. The severity of the disease in AD patients was evaluated using validated clinical scoring systems. Results Patients with AD had significant increases in plasma levels of NGF and SP compared with controls (P 〈 0·0005 and P 〈 0·0001, respectively). A positive correlation between the plasma levels of NGF and SP was found in AD patients (correlation coefficient, Cc = 0·920, P 〈 0·0001). There was a significant correlation of plasma NGF and SP levels with disease activity evaluated using three different scoring systems: the grading system of Rajka and Langeland (P 〈 0·001 and P 〈 0·01, respectively), the objective Severity Scoring of AD (Cc = 0·656, P 〈 0·005 and Cc = 0·752, P 〈 0·0005, respectively) and the Eczema Area and Severity Index (Cc = 0·740, P 〈 0·001 and Cc = 0·765, P 〈 0·005, respectively). Conclusions These data represent the first reported evidence of increased plasma levels of NGF and SP in an allergic human skin disease. They suggest that these neurogenic factors systemically modulate the allergic response in AD, probably through interactions with cells of the immune-inflammatory component. In addition, NGF and SP may be useful markers of disease activity in patients with AD.
package_name Blackwell Publishing
publikationsjahr_anzeige 2002
publikationsjahr_facette 2002
publikationsjahr_intervall 7999:2000-2004
publikationsjahr_sort 2002
publikationsort Oxford, UK
publisher Blackwell Science Ltd
reference 147 (2002), S. 0
search_space articles
shingle_author_1 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
shingle_author_2 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
shingle_author_3 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
shingle_author_4 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
shingle_catch_all_1 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
Blackwell Science Ltd
Summary Background Neurogenic components, such as neurotrophic factors and neuropeptides, are probably involved in the pathogenesis of atopic dermatitis (AD) via the neuroimmunocutaneous system. Numerous in vitro and in vivo studies have shown that nerve growth factor (NGF), the best-characterized member of the neurotrophin family, modulates the synthesis of the neuropeptide substance P (SP), both of which may be associated with the pathogenesis of human allergic diseases. Objectives To evaluate the levels of NGF and SP in the plasma of patients with AD and to examine their possible correlation with disease activity. Methods We measured plasma levels of NGF by an immunoenzymatic assay and of SP by aradioimmunoassay in 52 patients with AD, and compared them with 35 normal non-atopic controls. The severity of the disease in AD patients was evaluated using validated clinical scoring systems. Results Patients with AD had significant increases in plasma levels of NGF and SP compared with controls (P 〈 0·0005 and P 〈 0·0001, respectively). A positive correlation between the plasma levels of NGF and SP was found in AD patients (correlation coefficient, Cc = 0·920, P 〈 0·0001). There was a significant correlation of plasma NGF and SP levels with disease activity evaluated using three different scoring systems: the grading system of Rajka and Langeland (P 〈 0·001 and P 〈 0·01, respectively), the objective Severity Scoring of AD (Cc = 0·656, P 〈 0·005 and Cc = 0·752, P 〈 0·0005, respectively) and the Eczema Area and Severity Index (Cc = 0·740, P 〈 0·001 and Cc = 0·765, P 〈 0·005, respectively). Conclusions These data represent the first reported evidence of increased plasma levels of NGF and SP in an allergic human skin disease. They suggest that these neurogenic factors systemically modulate the allergic response in AD, probably through interactions with cells of the immune-inflammatory component. In addition, NGF and SP may be useful markers of disease activity in patients with AD.
1365-2133
13652133
shingle_catch_all_2 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
Blackwell Science Ltd
Summary Background Neurogenic components, such as neurotrophic factors and neuropeptides, are probably involved in the pathogenesis of atopic dermatitis (AD) via the neuroimmunocutaneous system. Numerous in vitro and in vivo studies have shown that nerve growth factor (NGF), the best-characterized member of the neurotrophin family, modulates the synthesis of the neuropeptide substance P (SP), both of which may be associated with the pathogenesis of human allergic diseases. Objectives To evaluate the levels of NGF and SP in the plasma of patients with AD and to examine their possible correlation with disease activity. Methods We measured plasma levels of NGF by an immunoenzymatic assay and of SP by aradioimmunoassay in 52 patients with AD, and compared them with 35 normal non-atopic controls. The severity of the disease in AD patients was evaluated using validated clinical scoring systems. Results Patients with AD had significant increases in plasma levels of NGF and SP compared with controls (P 〈 0·0005 and P 〈 0·0001, respectively). A positive correlation between the plasma levels of NGF and SP was found in AD patients (correlation coefficient, Cc = 0·920, P 〈 0·0001). There was a significant correlation of plasma NGF and SP levels with disease activity evaluated using three different scoring systems: the grading system of Rajka and Langeland (P 〈 0·001 and P 〈 0·01, respectively), the objective Severity Scoring of AD (Cc = 0·656, P 〈 0·005 and Cc = 0·752, P 〈 0·0005, respectively) and the Eczema Area and Severity Index (Cc = 0·740, P 〈 0·001 and Cc = 0·765, P 〈 0·005, respectively). Conclusions These data represent the first reported evidence of increased plasma levels of NGF and SP in an allergic human skin disease. They suggest that these neurogenic factors systemically modulate the allergic response in AD, probably through interactions with cells of the immune-inflammatory component. In addition, NGF and SP may be useful markers of disease activity in patients with AD.
1365-2133
13652133
shingle_catch_all_3 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
Blackwell Science Ltd
Summary Background Neurogenic components, such as neurotrophic factors and neuropeptides, are probably involved in the pathogenesis of atopic dermatitis (AD) via the neuroimmunocutaneous system. Numerous in vitro and in vivo studies have shown that nerve growth factor (NGF), the best-characterized member of the neurotrophin family, modulates the synthesis of the neuropeptide substance P (SP), both of which may be associated with the pathogenesis of human allergic diseases. Objectives To evaluate the levels of NGF and SP in the plasma of patients with AD and to examine their possible correlation with disease activity. Methods We measured plasma levels of NGF by an immunoenzymatic assay and of SP by aradioimmunoassay in 52 patients with AD, and compared them with 35 normal non-atopic controls. The severity of the disease in AD patients was evaluated using validated clinical scoring systems. Results Patients with AD had significant increases in plasma levels of NGF and SP compared with controls (P 〈 0·0005 and P 〈 0·0001, respectively). A positive correlation between the plasma levels of NGF and SP was found in AD patients (correlation coefficient, Cc = 0·920, P 〈 0·0001). There was a significant correlation of plasma NGF and SP levels with disease activity evaluated using three different scoring systems: the grading system of Rajka and Langeland (P 〈 0·001 and P 〈 0·01, respectively), the objective Severity Scoring of AD (Cc = 0·656, P 〈 0·005 and Cc = 0·752, P 〈 0·0005, respectively) and the Eczema Area and Severity Index (Cc = 0·740, P 〈 0·001 and Cc = 0·765, P 〈 0·005, respectively). Conclusions These data represent the first reported evidence of increased plasma levels of NGF and SP in an allergic human skin disease. They suggest that these neurogenic factors systemically modulate the allergic response in AD, probably through interactions with cells of the immune-inflammatory component. In addition, NGF and SP may be useful markers of disease activity in patients with AD.
1365-2133
13652133
shingle_catch_all_4 Toyoda, M.
Nakamura, M.
Makino, T.
Hino, T.
Kagoura, M.
Morohashi, M.
Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
Blackwell Science Ltd
Summary Background Neurogenic components, such as neurotrophic factors and neuropeptides, are probably involved in the pathogenesis of atopic dermatitis (AD) via the neuroimmunocutaneous system. Numerous in vitro and in vivo studies have shown that nerve growth factor (NGF), the best-characterized member of the neurotrophin family, modulates the synthesis of the neuropeptide substance P (SP), both of which may be associated with the pathogenesis of human allergic diseases. Objectives To evaluate the levels of NGF and SP in the plasma of patients with AD and to examine their possible correlation with disease activity. Methods We measured plasma levels of NGF by an immunoenzymatic assay and of SP by aradioimmunoassay in 52 patients with AD, and compared them with 35 normal non-atopic controls. The severity of the disease in AD patients was evaluated using validated clinical scoring systems. Results Patients with AD had significant increases in plasma levels of NGF and SP compared with controls (P 〈 0·0005 and P 〈 0·0001, respectively). A positive correlation between the plasma levels of NGF and SP was found in AD patients (correlation coefficient, Cc = 0·920, P 〈 0·0001). There was a significant correlation of plasma NGF and SP levels with disease activity evaluated using three different scoring systems: the grading system of Rajka and Langeland (P 〈 0·001 and P 〈 0·01, respectively), the objective Severity Scoring of AD (Cc = 0·656, P 〈 0·005 and Cc = 0·752, P 〈 0·0005, respectively) and the Eczema Area and Severity Index (Cc = 0·740, P 〈 0·001 and Cc = 0·765, P 〈 0·005, respectively). Conclusions These data represent the first reported evidence of increased plasma levels of NGF and SP in an allergic human skin disease. They suggest that these neurogenic factors systemically modulate the allergic response in AD, probably through interactions with cells of the immune-inflammatory component. In addition, NGF and SP may be useful markers of disease activity in patients with AD.
1365-2133
13652133
shingle_title_1 Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
shingle_title_2 Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
shingle_title_3 Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
shingle_title_4 Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
sigel_instance_filter dkfz
geomar
wilbert
ipn
albert
source_archive Blackwell Publishing Journal Backfiles 1879-2005
timestamp 2024-05-06T08:11:16.768Z
titel Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
titel_suche Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis
topic WW-YZ
uid nat_lic_papers_NLZ242123910